The South Korean National Institute of Health on Tuesday announced that they have begun the last stage testing for SK Bioscience’s coronavirus vaccine GBP510 this week.
According to reports, the GBP510 is currently in the third and last phase of its clinical trial, whilst making it a home-grown COVID-19 vaccine that is closest to becoming the country’s first vaccine to be authorized.
Director of the National Institute of Health, Kwon Jun-wook commented that the last and most important step for the commercialization of the first Korea-made COVID-19 vaccine has begun. And they would do the best to support it until the end through a solid public-private cooperation system.
About the final test –
• The test will assess the production rate of neutralizing antibodies that will offset virus infection and induce preventive effects.
• Hence, the more neutralizing antibodies are produced, the higher chances of counterbalancing the virus are secured with a stronger immune system.
According to reports, the NIH in order to increase the level of trust in the vaccine evaluation has signed a memorandum of understanding with the International Vaccine Institute earlier in August that set the standards for testing COVID-19 vaccine’s neutralizing antibodies.
Director general of the International Vaccine Institute, Jerome Kim commented that the effectiveness evaluation using verified testing methods is an essential part of approval for the use of vaccines. And that they will cooperate with the NIH so that the vaccine can be commercialized and used at home and abroad as soon as possible.
According to the Korea Disease Control and Prevention Agency, aside from SK Bioscience, a total of seven companies were in the process of undergoing early phase trials in developing their own COVID-19 vaccines as of Dec. 15.
The country’s new coronavirus cases on Tuesday were recorded below 6,000 for the second day in a row, however, the number of new critically ill patients went on to exceed by 1,000 again.
The Korea Disease Control and Prevention Agency (KDCA), the country added 5,202 more COVID-19 cases, this includes 5,144 local infections, thus bringing the cumulative total to 575,615.